EGFR/ErbB-2/ErbB-4 inhibitor-2
规格
| Cas Number | 179248-61-4 |
| 规格或纯度 | Moligand™, ≥98% |
| 级别 | Moligand™ |
| 纯度 | ≥98% |
| 包装 | 100mg 或 50mg 或 10mg 或 1mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| Action Type | 抑制剂 |
| Mechanism Of Action | 表皮生长因子受体抑制剂；erb-b2 受体酪氨酸激酶 2 抑制剂 |
| 溶解性 | Soluble in DMSO, and methanol. |
| 简短描述 | EGFR和c-erbB2的有效可逆抑制剂 |
| 英文简短描述 | a potent reversible inhibitor of EGFR and c-erbB2 |
| 过滤标签 | epidermal growth factor receptor Inhibitor,erb-b2 receptor tyrosine kinase 2 Inhibitor,EGFR,JAK/STAT Signaling,Protein Tyrosine Kinase/RTK |
| 储存温度 | 避光,-20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 描述 |
EGFR / ErbB-2抑制剂是细胞可渗透的4-苯胺基喹唑啉化合物，其是EGFR和c-erbB2的有效，可逆和ATP竞争性抑制剂（分别为IC | 50 | = 20 nM和79 nM），成员参与乳腺癌发展和进程的I型生长因子受体家族。已显示可有效抑制过度表达EGRF或Neu（c-erbB-2）的肿瘤细胞的增殖（IC | 50 |〜1.2-2.5μM）。 |
| 英文描述 |
EGFR/ErbB-2 Inhibitor is a cell-permeable 4-anilino quinazoline compound that acts a potent, reversible, and ATP-competitive inhibitors of EGFR and c-erbB2 (IC|50|= 20 nM & 79 nM, respectively), members of the type I growth factor receptor family that is involved in breast cancer development and progression. Shown to effectively inhibit the proliferation (IC|50|~ 1.2-2.5 μM) of tumor cells overexpressing EGRF or Neu (c-erbB-2). |